Home / Stocks / Lotus Eye Hosp & Inst L
LOTUSEYE

Lotus Eye Hosp & Inst L Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹102.25

Change

+0.95 (0.94%)

Open

₹101.52

Prev. Close

₹101.3

Day High

₹103.79

Day Low

₹100.82

Volume Analysis

Traded

67,047

Delivered

62,703

Delivery %

93.52%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (2)

  • •Promoter holding is falling
  • •Below-average fundamentals quality score (46/100)

Opportunities (0)

No signal for this stock

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹106.73 ₹105.26 ₹103.76 ₹102.29 ₹100.79 ₹99.32 ₹97.82
Fibonacci ₹105.26 ₹104.13 ₹103.42 ₹102.29 ₹101.16 ₹100.45 ₹99.32
Camarilla ₹103.07 ₹102.79 ₹102.52 ₹102.29 ₹101.98 ₹101.71 ₹101.43

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-15.11%

1 Week

-0.8%

1 Month

-7.32%

3 Months

-11.55%

6 Months

-6.36%

1 Year

-2.92%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

DuPont ROE Breakdown

0.13%

Net margin 0.15% × asset turnover 0.53x × equity multiplier 1.64x

Company Overview

Sector

Healthcare

Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.

TopFund Analysis

Lotus Eye Hosp & Inst L scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 46/100. The strongest factor is Financial Strength (88/100), while Growth (19/100) is the weakest area to weigh before deciding. Notably: Promoter holding is falling; below-average fundamentals quality score (46/100).

TopFund Score — Fundamentals Quality

46/100 — Weak

Data confidence: 74/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

88

Growth

19

Cash Flow

47

Corporate Governance

43

Institutional Ownership

30

Business Quality

42

Risk & Volatility

51

Liquidity

50

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Newspaper Advertisements published for Standalone Unaudited Financial Results for the quarter and half year ended September 30, 2026.

Q2 FY27 revenue rose 36% to ₹17.72 crore; H1 revenue up 31% and net profit up 59%.

Q2/H1 FY27 unaudited results approved; net profit Rs105.32 lakh.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 (S) Dec 2023 (S) Mar 2024 (S) Jun 2024 (S) Sep 2024 (S) Dec 2024 (S) Mar 2025 (S) Jun 2025 (S) Sep 2025 (S) Dec 2025 (S) Mar 2026 (S) Jun 2026 (S) Sep 2026 (S)
Sales + 13 12 11 13 13 12 12 14 13 14 14 17 18
Expenses + 11 10 10 11 12 11 12 12 12 13 13 14 15
Operating Profit 2 2 1 2 1 1 0 1 1 1 0 3 3
OPM % 14.22% 13.13% 6.99% 12.88% 8.91% 6.45% -1.48% 10.95% 5.9% 4.87% 3.53% 17.29% 14.39%
Other Income + 0 0 0 0 0 0 1 0 0 0 0 0 0
Interest 0 0 0 0 0 0 0 0 0 0 0 1 1
Depreciation 1 1 1 1 1 1 -1 1 1 1 1 2 2
Profit before tax 1 1 0 1 0 0 1 1 0 0 0 1 1
Tax % 28.57% 26.67% -200.0% 28.24% 9.09% -44.19% 70.24% 24.66% -71.43% -29.73% -33.33% 39.6% 21.43%
Net Profit + 1 1 0 1 0 0 0 1 0 0 0 1 0
EPS in Rs 0 0 0 0 0 0 0 0 0 0 0 0 0
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 7 -1 -3 3 1 2 6 5 1 11 18 26 36

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S)
Sales + 30 31 34 38 38 41 32 39 47 48 50 54
Expenses + 28 27 31 34 35 37 29 33 39 42 46 50
Operating Profit 2 4 3 4 3 4 4 6 8 7 4 4
OPM % 7.29% 12.82% 9.81% 11.42% 8.38% 9.82% 11.19% 15.22% 16.33% 13.76% 7.18% 6.61%
Other Income + 0 1 1 1 1 0 1 1 1 1 1 1
Interest 0 0 0 0 0 0 0 0 0 0 0 1
Depreciation 5 4 3 3 3 3 2 3 3 4 3 4
Profit before tax -2 0 0 2 1 1 2 4 6 4 1 0
Tax % -10.81% -400.0% -7.14% -2.35% -12.7% 26.9% 21.11% 27.14% 27.79% 27.43% 46.38% -280.0%
Net Profit + -2 0 0 2 1 1 2 3 4 3 1 0
EPS in Rs -1 0 0 1 0 1 1 1 2 1 0 0
Dividend Payout % 0.0% 0.0% 236.36% 59.43% 0.0% 0.0% 66.24% 34.9% 25.49% 0.0% 0.0% 0.0%
Sales growth 4 4 9 12 1 6 -20 20 21 2 3 8

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S) Sep 2026 (S)
Reserves 29 29 29 30 29 30 32 34 37 39 39 39 40
Borrowings + 1 1 0 0 0 0 0 1 1 1 3 16 31
Other Liabilities + 6 5 4 7 6 7 6 6 5 6 6 7 9
Total Liabilities 56 55 55 58 57 58 59 62 63 67 70 83 101
Fixed Assets + 47 44 41 43 44 43 41 44 44 49 54 66 76
CWIP 0 0 1 0 0 0 0 0 0 0 0 0 0
Investments 0 0 0 0 0 0 0 0 0 0 0 0 0
Other Assets + 9 11 13 15 12 15 19 18 19 18 16 17 24
Total Assets 56 55 55 58 57 58 59 62 63 67 70 83 101
Equity Capital 21 21 21 21 21 21 21 21 21 21 21 21 21

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S)
Cash from Operating Activity + 2 3 3 6 4 5 3 4 4 6 3 3
Cash from Investing Activity + -5 -1 -1 -4 -4 -1 0 -4 -2 -5 -6 -14
Cash from Financing Activity + 2 -1 0 -2 -1 0 0 -2 -2 -3 -2 9
Net Cash Flow 0 2 2 0 -1 4 3 -1 0 -2 -5 -2
Free Cash Flow -2 2 2 2 0 4 3 0 1 0 -2 -10
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 109 85 92 142 134 132 84 89 76 101 94 94

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 56.58% → 40.14%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 43.42% 58.6% 59.76% 59.97% 59.82% 59.73% 59.57% 59.33% 59.31% 59.85% 59.85% 59.85%
Promoters 56.58% 41.4% 40.24% 40.03% 40.14% 40.22% 40.39% 40.63% 40.66% 40.14% 40.14% 40.14%
FII 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.01% 0.0% 0.01% 0.0% 0.0% 0.0%
DII 0.0% 0.0% 0.0% 0.0% 0.04% 0.04% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Lotus Eye Hosp & Inst L (this stock) — — — —
Sun Pharmaceutical Ind L 451,075 36.7 5.05 16.0%
Divi S Laboratories Ltd 294,139 86.1 16.34 16.5%
Torrent Pharmaceuticals L 177,632 81.8 9.67 27.4%
Apollo Hospitals Enter. L 125,893 55.6 11.86 21.5%
Laurus Labs Limited 125,380 93.6 20.73 18.3%
Zydus Lifesciences Ltd 118,693 26.2 4.27 21.2%

Which Mutual Funds Hold Lotus Eye Hosp & Inst L?

Frequently Asked Questions about Lotus Eye Hosp & Inst L

Community Sentiment

What are other investors saying about Lotus Eye Hosp & Inst L?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.